4.6 Review

Molecular aspects of rheumatoid arthritis: role of transcription factors

期刊

FEBS JOURNAL
卷 275, 期 18, 页码 4463-4470

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1742-4658.2008.06582.x

关键词

NFAT; NF-kappa B; rheumatoid arthritis; transcription factors

向作者/读者索取更多资源

Rheumatoid arthritis is a multifactorial disease characterized by chronic inflammation of the joints. Both genetic and environmental factors are involved in the pathogenesis leading to joint destruction and ultimately disability. In the inflamed RA joint the synovium is highly infiltrated by CD4(+) T cells, B cells and macrophages, and the intimal lining becomes hyperplastic owing to the increased number of macrophage-like and fibroblast-like synoviocytes. This hyperplastic intimal synovial lining forms an aggressive front, called pannus, which invades cartilage and bone structures, leading to the destruction and compromised function of affected joints. This process is mediated by a number of cytokines (tumor necrosis factor-alpha, interleukin-1, interleukin-6, interleukin-17 interferon-gamma, etc.), chemokines (monocyte chemoattractant protein-1, monocyte chemoattractant protein-4 CCL18, etc.), cell adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1, etc.) and matrix metalloproteinases. Expression of these molecules is controlled at the transcription level and activation of a limited number of transcription factors is involved in this process.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

A simple screening test to assess risk of falls in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study

Koei Oh, Takefumi Furuya, Eisuke Inoue, Eiichi Tanaka, Katsunori Ikari, Atsuo Taniguchi, Hisashi Yamanaka, Ken Okazaki, Masayoshi Harigai

MODERN RHEUMATOLOGY (2021)

Review Rheumatology

Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

Eiichi Tanaka, Yutaka Kawahito, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yuko Kaneko, Hiroya Tamai, Yohei Seto, Akio Morinobu, Takahiko Sugihara, Atsuko Murashima, Masayo Kojima, Masaaki Mori, Hiromu Ito, Toshihisa Kojima, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Takeo Nakayama, Hisashi Yamanaka, Masayoshi Harigai

Summary: The systematic review of 20 randomized controlled trials showed that biosimilars and reference bDMARDs were equally effective and safe for managing rheumatoid arthritis.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

Takahiko Sugihara, Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Yohei Seto, Toshihisa Kojima, Hiromu Ito, Masataka Kohno, Takeo Nakayama, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Atsuko Murashima, Masaaki Mori, Eiichi Tanaka, Shintaro Hirata, Mitsumasa Kishimoto, Hisashi Yamanaka, Masayo Kojima, Masayoshi Harigai

Summary: This study aims to provide an evidence base for developing CPG for the management of rheumatoid arthritis in older adults, by conducting a systematic literature review and assessing the quality of evidence, yielding conclusions on the efficacy and safety of different drug treatments for older RA patients.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Factors associated with frailty in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study

Takefumi Furuya, Koei Oh, Katsunori Ikari, Eisuke Inoue, Eiichi Tanaka, Hisashi Yamanaka, Masayoshi Harigai

Summary: In this study of 3290 Japanese patients with RA, 16.7% were categorized as frail, 62.7% as prefrail, and 20.6% as robust. Factors such as BMI (both overweight and underweight), DAS28, J-HAQ, EQ-5D, NSAID use, and MTX nonuse were significantly associated with frailty.

CLINICAL RHEUMATOLOGY (2022)

Article Rheumatology

Effectiveness and safety of subcutaneous abatacept in biologic-naive RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study)

Naoto Tamura, Takanori Azuma, Kenta Misaki, Rei Yamaguchi, Fuminori Hirano, Eiji Sugiyama, Daisuke Kanai, Yohko Murakawa, Motohiro Oribe, Takahito Kimata, Kazutoshi Aoki, Tomoko Sugiura, Koji Takasugi, Yuya Takakubo, Yasuyuki Tomita, Takeo Isozaki, Toshihiro Nanki, Naooki Katsuyama, Takanori Kuroiwa, Hideto Oshikawa, Motohide Kaneko, Hiroshi Fujinaga, Kiwamu Saito, Eiichi Tanaka, Eisuke Inoue, Yuri Yoshizawa, Shigeru Matsumoto, Hisashi Yamanaka, Masayoshi Harigai

Summary: This study aimed to evaluate the effectiveness and safety of abatacept in biologic-naive rheumatoid arthritis patients with moderate disease activity. The results showed that abatacept significantly improved disease activity, physical disability, and quality of life over 52 weeks. The incidence of adverse events was relatively high.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study

Yoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Yuko Kaneko, Tsutomu Takeuchi, Koichi Amano, Naoki Iwamoto, Atsushi Kawakami, Miho Murakami, Norihiro Nishimoto, Tatsuya Atsumi, Takayuki Sumida, Koichiro Ohmura, Tsuneyo Mimori, Hisashi Yamanaka, Keishi Fujio, Yoshihisa Fujino, Kazuyoshi Saito, Kazuhisa Nakano, Shintaro Hirata, Shingo Nakayamada

Summary: In patients with rheumatoid arthritis who achieved sustained remission, continuing treatment, dose reduction, or discontinuation of methotrexate and dose reduction of biologic disease-modifying antirheumatic drugs (bDMARDs) achieved comparable disease control after one year. Subsequent de-escalation of methotrexate had no impact on disease control but decreased adverse events in year two.

RHEUMATOLOGY (2022)

Article Rheumatology

Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai

Summary: This study aimed to update the clinical practice guidelines for the management of rheumatoid arthritis (RA) in Japan and develop an algorithm for non-drug and surgical treatments. The guidelines were updated using the Grading of Recommendations, Assessment, Development, and Evaluation method, and recommendations were developed based on 19 clinical questions regarding non-drug and surgical treatments. The study also created an original algorithm for the treatment of RA.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort

Eiichi Tanaka, Eisuke Inoue, Mai Abe, Kumiko Saka, Eri Sugano, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai

Summary: The Japan College of Rheumatology has updated the clinical practice guidelines for rheumatoid arthritis, providing a useful tool for rheumatologists, healthcare professionals, and patients to make shared decisions in various clinical situations.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis

Hisashi Yamanaka, Yoshiya Tanaka, Toshihiko Hibino, Gopalakrishnan Unmesh, Chirag Shah, Dhananjay Bakhle, Dimitris Stefanidis

Summary: YLB113 biosimilar demonstrated long-term safety and sustained efficacy in patients with rheumatoid arthritis. In a post-hoc analysis, patients treated with YLB113 experienced significantly lower incidence of injection-site reactions and injection-site erythema compared with the reference product.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Multidisciplinary Sciences

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data

Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

Summary: This study investigated the cost-effectiveness of abatacept as first-line therapy for Japanese RA patients. The results showed that abatacept as first-line therapy had a favorable cost-effectiveness profile, leading to cost savings for Japanese healthcare payers.

PLOS ONE (2022)

Article Rheumatology

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt

Summary: This study aimed to evaluate the safety of baricitinib compared to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. The results showed an increased risk of venous thromboembolism (VTE) with baricitinib compared to TNFi treatment. Although the risk was slightly higher for major adverse cardiovascular events (MACE) and serious infection, the point estimates varied.

RHEUMATOLOGY AND THERAPY (2023)

Article Rheumatology

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naive to or switched from biologics

Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka, Hisashi Yamanaka

Summary: The post-marketing surveillance study evaluated the safety and efficacy of CT-P13, the first biosimilar of IFX, in real-world settings. CT-P13 showed excellent effectiveness as first-line therapy and clinical improvement in patients who switched from IFX or other bDMARDs. CT-P13 could be a cost-effective alternative to IFX in the treatment of rheumatoid arthritis.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids

Rei Yamaguchi, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Mai Abe, Eri Sugano, Naohiro Sugitani, Kumiko Saka, Moeko Ochiai, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

Summary: In the biologics era, risk factors for herpes zoster in rheumatoid arthritis patients include age, Health Assessment Questionnaire score, methotrexate use, and biologic use, while corticosteroid use and doses were decreasing.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort

Eri Sugano, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Mai Abe, Kumiko Saka, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka, Masayoshi Harigai

Summary: Few rheumatoid arthritis patients met the inclusion criteria of RCTs in clinical settings. There was a difference in the efficacy/effectiveness of bDMARDs between RCTs and clinical practice.

MODERN RHEUMATOLOGY (2022)

暂无数据